Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Cryo-Cell International Inc. CCEL

Healthcare  —  Medical Care Facilities
4.24 0.21 5.21% as of 25 Sep
Market cap
$32.5M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Cryo-Cell International Inc. (CCEL) Business Profile

Updated before January 2025

Company Overview

Cryo-Cell International Inc. (CCEL) is a pioneering biotechnology company specializing in the cryopreservation of umbilical cord blood and tissue. Founded in 1989, the company is headquartered in Oldsmar, Florida, and is recognized as the first private cord blood bank in the United States. Over the years, Cryo-Cell has established itself as a leader in the field of regenerative medicine, offering innovative solutions for families seeking to preserve potentially life-saving biological materials. The company is publicly traded on the OTCQB market under the ticker symbol CCEL.

Cryo-Cell’s leadership team is composed of experienced professionals with a strong background in biotechnology and healthcare. The company’s CEO, David Portnoy, has been instrumental in driving Cryo-Cell’s growth and maintaining its position as a market leader. Under his leadership, the company has expanded its service offerings and strengthened its commitment to research and development.

Core Business Segments

Cryo-Cell International operates across several core business segments, each focused on providing cutting-edge solutions in the field of cryopreservation and regenerative medicine.

Cord Blood Banking

Cryo-Cell’s flagship service is the collection, processing, and storage of umbilical cord blood. Cord blood is a rich source of hematopoietic stem cells, which can be used in the treatment of over 80 diseases, including leukemia, lymphoma, and certain genetic disorders. The company offers:

  • Private Cord Blood Banking: Families can store their newborn’s cord blood for potential future use.
  • Public Cord Blood Donation: Cryo-Cell facilitates the donation of cord blood to public banks for use in transplants and research.

Cord Tissue Banking

In addition to cord blood, Cryo-Cell provides services for the collection and storage of umbilical cord tissue. Cord tissue contains mesenchymal stem cells (MSCs), which have shown promise in regenerative medicine applications, including the treatment of autoimmune diseases and orthopedic conditions.

Adipose Tissue Banking

Cryo-Cell has expanded its offerings to include the cryopreservation of adipose (fat) tissue. This service allows individuals to store stem cells derived from fat tissue, which can be used in future regenerative therapies.

Research and Development

Cryo-Cell is actively involved in research and development to explore new applications for stem cells. The company collaborates with leading research institutions to advance the field of regenerative medicine and develop innovative therapies.

Business Model

Cryo-Cell International operates on a subscription-based business model. Customers pay an initial fee for the collection and processing of biological materials, followed by an annual storage fee. This model provides a steady stream of recurring revenue, ensuring financial stability and enabling the company to invest in research and development.

The company also generates revenue through licensing agreements and partnerships with healthcare providers and research institutions. By leveraging its expertise in cryopreservation, Cryo-Cell has established itself as a trusted partner in the biotechnology industry.

Strategic Direction

Cryo-Cell International is committed to expanding its service offerings and advancing the field of regenerative medicine. Key strategic initiatives include:

  • Service Expansion: The company plans to introduce new cryopreservation services, such as the storage of additional biological materials like placental tissue and dental pulp.
  • Global Growth: Cryo-Cell aims to expand its presence in international markets, particularly in regions with growing demand for regenerative medicine solutions.
  • Sustainability Goals: The company is focused on implementing environmentally friendly practices in its operations, including the use of energy-efficient technologies and sustainable packaging materials.
  • Research Investments: Cryo-Cell continues to invest in research and development to explore new therapeutic applications for stem cells and enhance the efficacy of its services.

Competitive Landscape

Cryo-Cell International operates in a competitive market, facing competition from both private and public cord blood banks. Key competitors include:

  • Cord Blood Registry (CBR): One of the largest private cord blood banks in the United States.
  • ViaCord: A leading provider of cord blood and tissue banking services.
  • Public Cord Blood Banks: Non-profit organizations that collect and store cord blood for public use.

Cryo-Cell differentiates itself through its long-standing reputation, comprehensive service offerings, and commitment to innovation.

Risk Factors

Cryo-Cell faces several risks that could impact its business operations and financial performance:

  • Market Dependence: The company relies heavily on the demand for cord blood and tissue banking services. A decline in consumer interest could affect revenue.
  • Regulatory Challenges: Changes in regulations governing the collection and storage of biological materials could increase operational costs or limit service offerings.
  • Supply Chain Disruptions: The company depends on a reliable supply chain for the collection and transportation of biological materials. Disruptions could impact service quality.
  • Competition: Intense competition from other cord blood banks and emerging technologies could erode market share.

Recent Developments

Cryo-Cell has made significant strides in recent years, including:

  • New Service Offerings: The introduction of adipose tissue banking has expanded the company’s portfolio and attracted a broader customer base.
  • Research Collaborations: Partnerships with leading research institutions have advanced the development of new stem cell therapies.
  • Technological Innovations: Cryo-Cell has invested in state-of-the-art cryopreservation technologies to enhance the quality and reliability of its services.
  • Global Developments: The COVID-19 pandemic highlighted the importance of regenerative medicine, leading to increased interest in Cryo-Cell’s services.

Investment Considerations

Strengths

  • Market Leadership: Cryo-Cell is a pioneer in the cord blood banking industry with a strong reputation.
  • Recurring Revenue Model: The subscription-based model provides financial stability.
  • Innovation: The company’s focus on research and development positions it as a leader in regenerative medicine.

Risks

  • Market Volatility: Dependence on consumer demand for cord blood banking services.
  • Regulatory Risks: Potential changes in regulations could impact operations.
  • Competition: Intense competition from other providers.

Conclusion

Cryo-Cell International Inc. is a market leader in the field of cryopreservation and regenerative medicine. With a strong reputation, innovative service offerings, and a commitment to research and development, the company is well-positioned for future growth. While it faces challenges such as market dependence and regulatory risks, Cryo-Cell’s strategic initiatives and focus on innovation provide a solid foundation for long-term success.